Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse ...
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 ...
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
Recursion Pharmaceuticals is a pioneer in AI-powered drug discovery but faces challenges in monetizing its innovations and aligning management's vision with sustainable revenue paths. The company's ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion and the University of Utah’s Center for Technology & Venture Commercialization (TVC) have signed a memorandum of understanding to explore the launch, ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development. It remains to ...
Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...
Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results